Biocytogen 百奥赛图
7 significant filings since 29 May 2026: 1 on litigation, 2 on guarantee or financial assistance and 2 on new listing, and 2 other kinds. The latest, on 7 Aug 2026: 百奥赛图（北京）医药科技股份有限公司2026年半年度业绩预告的自愿性披露公告. On 7 Aug 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 391.87% to 412.71% from the same period a year earlier.
自 29 May 2026 起有 7 份重大公告：litigation 1 份、guarantee or financial assistance 2 份、new listing 2 份，另有 2 类。最新一份（7 Aug 2026）：百奥赛图（北京）医药科技股份有限公司2026年半年度业绩预告的自愿性披露公告。7 Aug 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 391.87% 至 412.71%。
The 80 most recent of 104. 最近 80 条，共 104 条。
Filings are held in full from 1 Jan 2026, broker reports from 2 Jan 2017 and results from 9 Apr 2019. 公告自 1 Jan 2026 起完整收录，研报自 2 Jan 2017 起，业绩自 9 Apr 2019 起。